Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?

Author： Yuan Yuhong   Hunt Richard H.  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.11, Iss.4-6, 2003-12, pp. : 337-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors: Clinical Implications

By Meagher E.A.  

Drug Safety, Vol. 26, Iss. 13, 2003-01 ,pp. : 913-924

Adis International

Access to resources Recommend Favorite

Cyclo-Oxygenase-2 Inhibitors and the Kidney: A Case for Caution

By Noroian G.   Clive D.  

Drug Safety, Vol. 25, Iss. 3, 2002-01 ,pp. : 165-172

Adis International

Access to resources Recommend Favorite

Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction: How Strong is the Link?

By Howes L.G.  

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 829-835

Adis International

Access to resources Recommend Favorite

Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?

By Bannwarth Bernard  

Drug Safety, Vol. 28, Iss. 3, 2005-01 ,pp. : 183-189

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.  

Clinical Pharmacokinetics, Vol. 38, Iss. 3, 2000-03 ,pp. : 225-242

Adis International

Access to resources Recommend Favorite